E

EPIMED GmbH | Berlin, Germany

Research site

(Unclaimed)

Location

Budapester Straße, 15-19, Berlin, Berlin, Germany

Site insights

Top conditions

Top treatments

Ritonavir

Emtricitabine

Tipranavir

Doravirine

Tenofovir

Rilpivirine

Tenofovir Disoproxil Fumarate

ISL

Islatravir

Elvitegravir

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 19 total trials

A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE

The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.

Enrolling

Ischemic Stroke; Ischemic Attack, Transient

Drug: Placebo

Drug: Milvexian

Efficacy Against Oral Persistent Infection, Immunogenicity and Safety of the 9-valent Human Papillomavirus Vaccine (9vHPV) in Men Aged 20-45 Years (V503-049)

The purpose of this study is to evaluate the efficacy, immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in men 20 to 45...

Active, not recruiting

Papillomavirus Infections

Biological: 9vHPV Vaccine

Other: Placebo (Saline for Injection)

Switch to Doravirine/Islatravir (DOR/ISL) in Human Immunodeficiency Virus 1 (HIV-1) Participants Treated With Bictegravir/Emtricitabine/Tenofovir Alafenamide (BIC/FTC/TAF) (MK-8591A-018)

This study will evaluate the safety and efficacy of a switch to MK-8591A (a fixed dose combination of doravirine and islatravir) in human immunodefic...

Active, not recruiting

HIV Infection

Drug: Placebo to BIC/FTC/TAF

Drug: Placebo to FDC DOR/ISL